Transcriptome of skin biopsies from Hidradenitis Suppurativa (HS) patients with anti-TNFalpha therapy.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with significant morbidity. The pathogenesis remains incompletely understood although immune dysregulation plays an important role. It is challenging to treat and approximately 50% of patients respond clinically to adalimumab, the only licensed treatment. We completed bulk RNA-sequencing on lesional and non-lesional skin samples of patients before and after 12-weeks treatment with adalimumab.